Persons at risk for psychosis overestimate social functioning compared to persons with major depressive disorder and community controls

Abstract

Poor insight is common in persons with psychosis, but treatment can improve insight. Individuals with psychosis who exhibit better insight have better social functioning, reduced negative symptoms, and paradoxically worse depression. There is limited research investigating insight among persons at clinical high risk for psychosis (CHR).

Understanding the relationship between insight, social functioning, negative symptoms, and depression might inform treatment. We focused on introspective bias (IB), the overestimation or underestimation of social functioning. Persons with CHR (N = 36), Major Depressive Disorder (MDD; N = 164), and community controls (N = 60) were recruited from the Multisite Assessment of Psychosis-risk Study and completed clinical interviews and self-report instruments. The estimation type was operationalized by whether a person was above or below the standardized mean difference between self-reported and interviewer-rated social functioning.

We hypothesized that 1) persons at CHR would have less depressive symptom severity than those with MDD diagnoses, but more depressive symptom severity than control participants accounting for IB within diagnostic groups, 2) CHR and MDD participants would endorse higher levels of negative symptoms, viewed transdiagnostically (e.g., anhedonia, avolition), than controls but not each other, 3) overestimators would endorse higher levels of negative symptoms and depression than underestimators, 4) CHR participants would have the greatest proportions of overestimators, MDD would have the greatest proportion of underestimators, and control participants would have equal proportions of under- and overestimators.

Those at CHR had more overestimators, overestimators overall had worse depression and negative symptoms, and diagnostic group membership did not impact the effects of IB on symptoms. This study suggests that IB has clinically relevant correlates but is not a primary treatment target for persons at CHR.